Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
Lantern Pharma Inc. (LTRN)
Company Research
Source: Business Wire
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies.Clinical benefit observed in 48% of evaluable cancer patients at or above the therapeutic dose threshold.Durable clinical benefits were observed in hard-to-treat tumors like glioblastoma multiforme (GBM), gastrointestinal stromal tumor (GIST) and thymic carcinoma.Biomarker insights highlight potential in DDR-mutated cancers, with marked tumor reductions in patients with CHK2, ATM, and STK11/KEAP1 alterations.Recommended Phase 2 dose (RP2D) established for targeted Phase 1b/2 trials in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and bladder cancer.The cancer indications in these targeted trials represent markets exceeding $6 billion in annual potential.The observations for LP-184 in the Phase 1a trial include clinical benefit for multiple patients who had
Show less
Read more
Impact Snapshot
Event Time:
LTRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LTRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LTRN alerts
High impacting Lantern Pharma Inc. news events
Weekly update
A roundup of the hottest topics
LTRN
News
- Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 TrialsBusiness Wire
- Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
LTRN
Earnings
- 8/13/25 - Beat
LTRN
Sec Filings
- 11/13/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 9/23/25 - Form 8-K
- LTRN's page on the SEC website